MUSC/HCC Paul Calabresi Clinical Oncology Training Program Plan

MUSC/HCC Paul Calabresi 临床肿瘤学培训计划计划

• 批准号: 9242567
• 负责人: MICHAEL B LILLY
• 金额: $ 53.71万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2018-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9242567
• 关键词: Adult; Antineoplastic Agents; Applications Grants; Appointment; Area; Award; Basic Science; Biological; Cancer Center; Charge; Childhood; Clinic; Clinical; Clinical Oncology; Clinical Research; Clinical Sciences; Communities; Dental; Discipline of Nursing; Doctor of Pharmacy; Doctor of Philosophy; Ensure; Faculty; Funding; Funding Agency; Goals; Gynecologic Oncology; Laboratories; Laboratory Research; Malignant Neoplasms; Master of Science; Medical; Medicine; Mentored Clinical Scientist Development Program; Mentors; Monitor; National Cancer Institute; Neurologic; Nurses; Operative Surgical Procedures; Otolaryngology; Participant; Pharmacy facility; Population Sciences; Postdoctoral Fellow; Prevention; Provider; Publishing; Qualifying; Radiation; Recruitment Activity; Reporting; Research; Research Personnel; Resources; Rotation; SECTM1 gene; Schedule; Science; Scientist; Senior Scientist; Services; South Carolina; Therapy trial; Time; Training; Training Programs; Translational Research; Translations; United States National Institutes of Health; Universities; Urology; Work; base; cancer care; cancer immunotherapy; cancer therapy; career development; clinical application; cohort; college; design; drug development; experience; insight; knowledge base; medical specialties; mortality disparity; next generation; oncology; patient oriented; patient oriented research; programs

DESCRIPTION (provided by applicant): The Medical University of South Carolina's Hollings Cancer Center (MUSC/HCC) is committed to providing a physical and intellectual space to nurture tomorrow's leaders in clinical and translational oncology research. To accomplish this end, MUSC/HCC will establish the Paul Calabresi Clinical & Translational Oncology Training Program focused in three areas - cancer drug development, cancer immunotherapy, and cancer population sciences. The goal of this Program is to train successful, patient-oriented, clinical- and laboratory-based investigators who can work effectively in a collaborative, translational research setting. At the completion of the Program, these researchers will be able to independently design, implement and manage patient-oriented studies emphasizing both the translation of laboratory research findings into clinical applications, as well as laboratory studis examining the basic mechanisms of poorly understood clinical phenomena. Chosen participants, called Calabresi Scholars, will already hold a clinical or basic science qualifying professional degree. Clinically oriented Scholars will have recently completed postgraduate training in medical (adult or pediatric), radiation, surgical (including urology, otolaryngology, ad neurological subspecialties), or gynecologic oncology and will be ready for a first faculty appointment. Basic science Scholars will have a PhD or PharmD, will have completed at least two years of post-doctoral experience, and will be ready to develop a clinically-oriented, but laboratory-based, research program. To ensure the maturation of their knowledge base in clinical and translational research, each MUSC/HCC Calabresi Scholar will use the support from this K12 to develop a training plan within one of the three tracks in conjunction with an experienced mentoring team comprised of senior scientists (MDs and PhDs). Training will entail intensive course work (potentially leading to a Master of Science in Clinical Research) and an opportunity to participate in multiple, short-term laboratory and clinical research rotations durin the first quarter of the first year of training. This will be followed by a continuous, mentored, longitudinal laboratory and clinical research experience during the remainder of the first and second years of training. Each Scholar will be expected to complete three different but related milestones. Each Scholar will design and initiate a clinical cancer therapy trial (MD/DO Scholars) or a correlative science study (PhD/PharmD scholars), to answer a biological hypothesis-based clinical research question. As a second milestone, at least two publishable research reports should emanate from each of the Scholar's studies. Finally, the Scholar will be expected to create a fully developed grant application and submit it to a funding agency. An interdisciplinary Advisory Council will work closely with the Program Co-Directors in Year 01 to finalize all of the details of each training component and to have adequate time to recruit, externally and internally, for the best cohort of Scholars. Beginning in Year 02, the Program will appoint one or two Scholars annually, for a total of six Scholars. This MUSC/HCC Calabresi Training Program has been designed for a two year commitment. The Scholars will be selected by the Advisory Council, and the Advisory Council will also be charged to carefully monitor and evaluate each Scholar and the overall Program on a frequent and regular schedule. All Program components will utilize the considerable experience of scientists and mentors originating from MUSC's Colleges of Medicine, Pharmacy, Dental Medicine, Nursing and Graduate Medical Sciences, as well as the considerable research resources provided by the Hollings Cancer Center, a National Cancer Institute designated cancer center. The Program will also take full advantage of the career development services as part of MUSC's NIH funded Clinical and Translational Science Award. This K12 Program will provide the opportunity to maximize the HCC's potential in patient-oriented research while ensuring that the next generation of scientists is prepared to expedite the translation of science into the clinic and community. Another hallmark feature of this proposed K12 Program is that it is based in South Carolina, a state characterized by high cancer mortality, disparities and limited specialty providers, thus affording the Scholars with exceptional insight into the potential challenges of disseminating new standards of cancer care, prevention, and control emanating from the latest research.

描述（由申请人提供）：南卡罗来纳医科大学霍林斯癌症中心（MUSC/HCC）致力于提供物理和智力空间，培养临床和转化肿瘤学研究的未来领导者。为了实现这一目标，MUSC/HCC将建立Paul Calabresi临床和转化肿瘤学培训计划，重点关注三个领域-癌症药物开发，癌症免疫治疗和癌症人口科学。该计划的目标是培养成功的，以患者为导向的，临床和实验室为基础的研究人员，他们可以在协作，转化研究环境中有效地工作。在完成课程后，这些研究人员将能够独立设计，实施和管理以患者为导向的研究，强调将实验室研究成果转化为临床应用，以及实验室研究检查鲜为人知的临床现象的基本机制。被选中的参与者被称为卡拉布雷西学者（Calabresi Scholars），他们将持有临床或基础科学专业学位。临床方向的学者将在近期完成医学（成人或儿科）、放射、外科（包括泌尿科、耳鼻喉科和神经专科）或妇科肿瘤学的研究生培训，并将为首次教员任命做好准备。基础科学学者将拥有博士学位或药学博士学位，将完成至少两年的博士后经验，并将准备开展以临床为导向，但以实验室为基础的研究项目。为了确保他们在临床和转化研究方面的知识基础成熟，每位MUSC/HCC Calabresi学者将利用K12的支持，在由资深科学家（医学博士和博士）组成的经验丰富的指导团队的指导下，在三个轨道之一中制定培训计划。培训将包括密集的课程学习（有可能获得临床研究理学硕士学位），并有机会在培训第一年的第一季度参加多个短期实验室和临床研究轮岗。在培训的第一年和第二年的剩余时间里，他们将获得连续的、有指导的、纵向的实验室和临床研究经验。每位学者将完成三个不同但相关的里程碑。每位学者将设计并启动临床癌症治疗试验（MD/DO学者）或相关科学研究（PhD/PharmD学者），以回答基于生物学假设的临床研究问题。作为第二个里程碑，每位学者的研究应至少发表两份可发表的研究报告。最后，学者将被要求创建一个完整的资助申请，并将其提交给资助机构。一个跨学科咨询委员会将在第1学年与项目联合主任密切合作，最终确定每个培训部分的所有细节，并有足够的时间在外部和内部招募最优秀的学者。从2002年开始，该项目每年将任命一至两名学者，共计六名学者。这个MUSC/HCC卡拉布雷西培训计划是为两年的承诺而设计的。这些学者将由咨询委员会选出，咨询委员会也将负责定期和频繁地对每位学者和整个项目进行仔细的监督和评估。所有项目的组成部分都将利用来自MUSC医学院、药剂学、牙科医学、护理学和研究生医学科学学院的科学家和导师的丰富经验，以及由霍林斯癌症中心（国家癌症研究所指定的癌症中心）提供的大量研究资源。该项目还将充分利用职业发展服务，作为MUSC国家卫生研究院资助的临床和转化科学奖的一部分。这个K12项目将提供机会，最大限度地发挥HCC在以患者为导向的研究中的潜力，同时确保下一代科学家准备好加速将科学转化为临床和社区。这个拟议的K12项目的另一个标志性特点是，它设在南卡罗来纳州，这个州的特点是癌症死亡率高，差异大，专业提供者有限，因此提供